SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 261 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $888 | +33.7% | 31,775 | +43.1% | 0.00% | +100.0% |
| Q2 2023 | $664 | -17.1% | 22,200 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $801 | +1.3% | 22,200 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $791 | -99.9% | 22,200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $730,000 | +16.6% | 22,200 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $626,000 | -12.9% | 22,200 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $719,000 | +18.8% | 22,200 | +9.9% | 0.00% | +100.0% |
| Q4 2021 | $605,000 | +14.2% | 20,200 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $530,000 | -14.1% | 19,700 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $617,000 | +20.0% | 19,700 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $514,000 | +4.9% | 19,700 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $490,000 | +21.9% | 19,700 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $402,000 | -63.9% | 19,700 | -51.5% | 0.00% | -71.4% |
| Q3 2019 | $1,115,000 | -32.8% | 40,600 | -21.6% | 0.01% | -12.5% |
| Q2 2019 | $1,659,000 | +20.3% | 51,800 | +63.4% | 0.01% | 0.0% |
| Q1 2019 | $1,379,000 | +63.4% | 31,700 | +22.4% | 0.01% | +33.3% |
| Q4 2018 | $844,000 | -38.8% | 25,900 | -18.3% | 0.01% | -25.0% |
| Q3 2018 | $1,379,000 | -27.3% | 31,700 | -2.5% | 0.01% | -33.3% |
| Q2 2018 | $1,896,000 | +101.9% | 32,500 | +58.5% | 0.01% | +100.0% |
| Q1 2018 | $939,000 | -20.6% | 20,500 | -20.8% | 0.01% | -33.3% |
| Q4 2017 | $1,182,000 | 0.0% | 25,900 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,182,000 | +6.6% | 25,900 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $1,109,000 | +37.1% | 25,900 | 0.0% | 0.01% | +28.6% |
| Q1 2017 | $809,000 | +14.9% | 25,900 | -7.8% | 0.01% | 0.0% |
| Q4 2016 | $704,000 | +10.0% | 28,100 | +8.1% | 0.01% | 0.0% |
| Q3 2016 | $640,000 | +24.0% | 26,000 | 0.0% | 0.01% | +16.7% |
| Q2 2016 | $516,000 | +63.3% | 26,000 | +23.8% | 0.01% | +50.0% |
| Q1 2016 | $316,000 | -6.2% | 21,000 | -14.6% | 0.00% | 0.0% |
| Q4 2015 | $337,000 | 0.0% | 24,600 | +2.5% | 0.00% | 0.0% |
| Q3 2015 | $337,000 | -14.5% | 24,000 | +3.4% | 0.00% | -20.0% |
| Q2 2015 | $394,000 | +62.1% | 23,200 | +15.4% | 0.01% | +66.7% |
| Q1 2015 | $243,000 | +29.9% | 20,100 | -12.6% | 0.00% | +50.0% |
| Q4 2014 | $187,000 | -13.8% | 23,000 | -8.0% | 0.00% | -33.3% |
| Q3 2014 | $217,000 | -17.5% | 25,000 | +4.2% | 0.00% | -25.0% |
| Q2 2014 | $263,000 | +43.7% | 24,000 | +17.1% | 0.00% | +33.3% |
| Q1 2014 | $183,000 | +34.6% | 20,500 | +17.1% | 0.00% | +50.0% |
| Q4 2013 | $136,000 | +6.2% | 17,500 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $128,000 | +21.9% | 17,500 | +6.1% | 0.00% | 0.0% |
| Q2 2013 | $105,000 | – | 16,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |